Drugs / TCR-transduced T cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05349890 | Apr 2023 → Apr 2027 expected | epithelial neoplasm | Providence Health & Services | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04520711 | Feb 2022 → Dec 2026 expected | epithelial neoplasm | Providence Health & Services | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02654821 | Mar 2012 → Oct 2019 | cutaneous melanoma, ocular melanoma | The Netherlands Cancer Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04520711 ↗ |
| Known as | TCR-T | “T-cell receptor gene-engineered T cells (TCR-T)” NCT04520711 ↗ |
| Modality | Cell therapy | “adoptive transfer of autologous, TCR transduced T cells” NCT02654821 ↗ |
| Route | Intravenous | “one single intravenous adoptive transfer of transduced T cells” NCT02654821 ↗ |